Proposal for Slightly Revised USP Chapter <711> Dissolution Published
![Statistical Simulations for Enhanced Understanding of Analytical Performance - Live Webinar](files/eca/userImages/training.img/Z-ECA-Webinar-Statistical-Simulations.jpg)
Recommendation
Monday, 9 September 2024 14.00 - 16.00 h
In November 2021, we reported that the Dosage Forms Expert Committee intends to revise General Chapter <711> Dissolution. Please read the related news article for more information.
The new version of the chapter was now published for comments in the current Pharmacopeial Forum, PF 48(2). The briefing note states that the "proposal is based on the version of the chapter to be official on May 1, 2022. The purpose of this revision is to include an option of using a new USP Reference Standard, USP Dissolution Performance Verification Standard-Prednisone RS, to qualify the Dissolution Apparatus 1 (basket) and Dissolution Apparatus 2 (paddle), in addition to USP Prednisone Tablets RS, which is already included in the official version of this chapter."
The proposal can be consulted after registration on the Pharmacopeial Forum website. Comments can be submitted until May 31, 2022. In the absence of significant adverse comments, it is proposed to implement the new revision via an Interim Revision Announcement with an official date of September 1, 2022.
Related GMP News
24.07.2024FDA Warning Letter to Chinese OTC Manufacturer for Lack of Analytical Test Data
10.07.2024Pharmeuropa: Two Revised Chapters on Dissolution Testing published for comments
03.07.2024FDA Warning Letter: GMP Requirements also apply to HPLC Analyses for Internal Use
12.06.2024NMPA Announcement on Application of ICH Q2(R2) and Q14 Principles
22.05.2024Q&As from the Live Online Training "Introduction to the AQCG's new AIQSV Guide" - Part 1
22.05.2024FDA Warning Letter to Contract Testing Laboratory in Uruguay due to Data Integrity Violations